Aplastic anemia classification: Difference between revisions
Jump to navigation
Jump to search
Iqra Qamar (talk | contribs) |
No edit summary |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Aplastic anemia}} | {{Aplastic anemia}} | ||
{{CMG}}; '''Associate Editor(s)-In-Chief:''' [[Priyamvada Singh|Priyamvada Singh, M.D.]] [mailto:psingh13579@gmail.com] {{N.F}} | {{CMG}}; '''Associate Editor(s)-In-Chief:''' [[Priyamvada Singh|Priyamvada Singh, M.D.]] [mailto:psingh13579@gmail.com] {{N.F}} | ||
==Overview== | ==Overview== | ||
| Line 15: | Line 13: | ||
{| class="wikitable" | {| class="wikitable" | ||
|+ '''Classification of aplastic anemia (two out of three criteria must be met)''' | |+ '''Classification of aplastic anemia (two out of three criteria must be met)''' | ||
! | !style="background: #4479BA; color: #FFFFFF; " | | ||
!nSAA | !style="background: #4479BA; color: #FFFFFF; " |nSAA | ||
!SAA | !style="background: #4479BA; color: #FFFFFF; " |SAA | ||
!vSAA | !style="background: #4479BA; color: #FFFFFF; " |vSAA | ||
|- | |- | ||
|[[Reticulocytes]] | | style="background: #DCDCDC; text-align: center;" |[[Reticulocytes]] | ||
|<20G/L | | style="background: #F5F5F5; text-align: center;" |<20G/L | ||
|<20G/L | | style="background: #F5F5F5; text-align: center;" |<20G/L | ||
|<20G/L | | style="background: #F5F5F5; text-align: center;" |<20G/L | ||
|- | |- | ||
|[[Platelet|Platelets]] | | style="background: #DCDCDC; text-align: center;" |[[Platelet|Platelets]] | ||
|<50 G / L | | style="background: #F5F5F5; text-align: center;" |<50 G / L | ||
|<20G/L | | style="background: #F5F5F5; text-align: center;" |<20G/L | ||
|<20G/L | | style="background: #F5F5F5; text-align: center;" |<20G/L | ||
|- | |- | ||
|[[Granulocytes|Neutrophilic granulocytes]] | | style="background: #DCDCDC; text-align: center;" |[[Granulocytes|Neutrophilic granulocytes]] | ||
|<1.0 G / L | | style="background: #F5F5F5; text-align: center;" |<1.0 G / L | ||
|<0.5G/L | | style="background: #F5F5F5; text-align: center;" |<0.5G/L | ||
|0.2G/L | | style="background: #F5F5F5; text-align: center;" |0.2G/L | ||
|} | |} | ||
This classification is of prognostic relevance and has an influence on therapeutic procedures. | This classification is of prognostic relevance and has an influence on therapeutic procedures. | ||
| Line 39: | Line 37: | ||
==Classification based on the presumed etiology== | ==Classification based on the presumed etiology== | ||
{| class="wikitable" | {| class="wikitable" | ||
|+ | |+Classification based on the presumed etiology | ||
|- | |- | ||
|[[Idiopathic]] | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; " |''Acquired aplastic anemia'' | ||
| | | style="background: #DCDCDC; text-align: center;" |[[Idiopathic]] | ||
| style="background: #F5F5F5; text-align: center;" | | |||
|- | |- | ||
| | | style="background: #DCDCDC; text-align: center;" |Secondary | ||
|[[Irradiation]] | | style="background: #F5F5F5; text-align: left;" | | ||
Drugs and chemicals: cytotoxic agents, [[benzene]], chloromphenicol, [[gold]] | * [[Irradiation]] | ||
* Drugs and chemicals: cytotoxic agents, [[benzene]], chloromphenicol, [[gold]] | |||
salts, [[Non-steroidal anti-inflammatory drug|NSAIDS]] | salts, [[Non-steroidal anti-inflammatory drug|NSAIDS]]. | ||
* [[Idiosyncratic drug reaction|Idiosyncratic]] reactions | |||
[[Idiosyncratic drug reaction|Idiosyncratic]] reactions | * Viruses: [[Epstein Barr virus]], [[parvovirus B19]], [[Human Immunodeficiency Virus (HIV)|HIV]] | ||
* Immune diseases | |||
Viruses: [[Epstein Barr virus]], [[parvovirus B19]], [[Human Immunodeficiency Virus (HIV)|HIV]] | * [[Pregnancy]] | ||
* [[PNH]] [[Paroxysmal nocturnal hemoglobinuria]] | |||
Immune diseases | |||
[[Pregnancy]] | |||
[[PNH]] [[Paroxysmal nocturnal hemoglobinuria]] | |||
|- | |- | ||
|'''''Inherited aplastic anemia''''' | | colspan="2" style="background: #4479BA; color: #FFFFFF; " |'''''Inherited aplastic anemia''''' | ||
|[[Fanconi anemia]] | | style="background: #F5F5F5; text-align: left;" | | ||
[[Dyskeratosis congenita|Dyskeratosis | * [[Fanconi anemia]] | ||
* [[Dyskeratosis congenita|Dyskeratosis congenita]] | |||
[[Amegakaryocytic thrombocytopenia]] | * [[Amegakaryocytic thrombocytopenia]] | ||
* [[Shwachman-Diamond syndrome]] | |||
[[Shwachman-Diamond syndrome]] | |||
|} | |} | ||
Latest revision as of 18:55, 29 October 2018
|
Aplastic anemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Aplastic anemia classification On the Web |
|
American Roentgen Ray Society Images of Aplastic anemia classification |
|
Risk calculators and risk factors for Aplastic anemia classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.D. [2] Nazia Fuad M.D.
Overview
Aplastic anemia may be classified according to blood cell counts into 3 subgroups, moderately severe aplastic anemia or non severe AA (nSAA), severe aplastic anemia (SAA), and very severe aplastic anemia(vSAA).
Classification
Aplastic anemia may be classified according to blood cell counts into 3 subgroups:[1]
- Moderately severe aplastic anemia or non severe AA (nSAA)
- Severe aplastic anemia (SAA)
- Very severe aplastic anemia(vSAA)
| nSAA | SAA | vSAA | |
|---|---|---|---|
| Reticulocytes | <20G/L | <20G/L | <20G/L |
| Platelets | <50 G / L | <20G/L | <20G/L |
| Neutrophilic granulocytes | <1.0 G / L | <0.5G/L | 0.2G/L |
This classification is of prognostic relevance and has an influence on therapeutic procedures.
Classification based on the presumed etiology
| Acquired aplastic anemia | Idiopathic | |
|---|---|---|
| Secondary |
salts, NSAIDS.
| |
| Inherited aplastic anemia | ||
References
- ↑ Dolberg OJ, Levy Y (2014). "Idiopathic aplastic anemia: diagnosis and classification". Autoimmun Rev. 13 (4–5): 569–73. doi:10.1016/j.autrev.2014.01.014. PMID 24424170.